Parexel Outlines Biopharma Advances And Increased Outsourcing
This article was originally published in The Pink Sheet Daily
Executive Summary
The CRO highlighted industry R&D success and an ever-expanding reliance on outsourcing at its June 26 investor day. Management said there are already more clinical development staff at CROs than within biopharma and suggested that soon more drug development will be done by CROs than drug manufacturers.
You may also be interested in...
CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.
Parexel Says It Is Ideally Positioned As Big Pharma Shakes Up R&D Efforts
Noting its recent five-year contract with Pfizer, the CRO predicts 13% revenue growth for fiscal 2012.
Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?